Catalysts / ENTA
Upcoming FDA decisions and readouts we track for Enanta Pharmaceuticals, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Enanta Pharmaceuticals (ENTA, listed on Nasdaq). They cover 2 programmes: EDP-978 (Chronic urticaria) and Zelicapavir (RSV in high-risk adults).
First on the list: the Phase 1 readout for EDP-978 (Chronic urticaria), guided by the company to Q4 2026. By stage, the upcoming rows are 1 Phase 1 readout and 1 Phase 2/3 readout.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals ENTA · Nasdaq | EDP-978 | Chronic urticaria | Q4 2026 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Enanta Pharmaceuticals ENTA · Nasdaq | Zelicapavir | RSV in high-risk adults | 2027 company guidance |
Phase 2/3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList